

Publikationen / Präsentationen

First Author / Senior Author (Peer reviewed original publications)

- Luna J, Kampe EOI, Aga-Barfknecht H, Lehne M, Kunk L, Hänsel I, Trescher S, Mevius A, Kissner A, **Kroeger N**, De Santis M. Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guérin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data. *World J Urol.* 2025 Nov 1;43(1):661. doi: 10.1007/s00345-025-06025-1. PMID: 41175231
- **Kroeger N**, Lebacle C, Hein J, Rao PN, Nejati R, Wei S, Burchardt M, Drakaki A, Strother M, Kutikov A, Uzzo R, Pantuck AJ. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. *Eur J Cancer.* 2022 Jun;168:68-76. doi: 10.1016/j.ejca.2022.03.023. Epub 2022 Apr 20. PMID: 35461012 (Impact Factor 10.002)
- Ribback S, Winter S, Klatte T, Schaeffeler E, Gellert M, Stühler V, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, **Kroeger N** Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. *World J Urol.* 2022 Mar;40(3):739-746. doi: 10.1007/s00345-021-03900-5. Epub 2021 Dec 2. PMID: 34859284 (Impact Factor 3.661)
- Diesing K, Ribback S, Winter S, Gellert M, Oster AM, Stühler V, Gläser E, Adler F, Hartwig C, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, **Kroeger N**. p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics. *J Cancer Res Clin Oncol.* 2021 Dec;147(12):3565-3576. doi: 10.1007/s00432-021-03786-1. Epub 2021 Sep 9. (Impact Factor 4.176)
- Heide J, Ribback S, Klatte T, Shariat S, Burchardt M, Dombrowski F, Belldgrun AS, Drakaki A, Pantuck AJ, **Kroeger N**. Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. *World J Urol.* 2020 Jun;38(6):1525-1533. doi: 10.1007/s00345-019-02930-4. Epub 2019 Sep 13. PMID: 31520111 (Impact Factor 4.22&)
- **Kroeger N**, Haoran L, GuillermoDe V, Donskov F, Sim H. W., Stühler V, Wells C.J, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Heng DY. Active smoking is associated with worse prognosis in metastatic renal cell carcinoma patients treated with targeted therapies. *Clinical Genitourinary Cancer.* Available online 12 September 2018, In Press, Accepted Manuscript, <https://doi.org/10.1016/j.clgc.2018.09.006> (Impact Factor 2,54).
- Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldgrun AS, Seliger B, Pantuck A, **Kroeger N**. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. *Urol Oncol.* 2018 Aug 28. pii: S1078-1439(18)30268-0. doi: 10.1016/j.urolonc.2018.07.013. [Epub ahead of print] (Impact Factor 3.40)
- Bedke J, Heide, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U,

- Pechoel M, Alkhayyat H, Shariat SF, Dombrowski F, Stenzl A, Burchardt M, Klatte T, **Kroeger N**. Microvascular and lymphovascular tumor invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice. *BJU Int*. 2018 Jan;121(1):84-92. doi: 10.1111/bju.13984. Epub 2017 Sep 10. PMID: 28803448 (Impact Factor (2016): 4,34)
- **Kroeger N**, Pantuck Aj, Wells C et al. Characterizing the Impact of Lymph Node Metastases on Survival Outcome of metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. *Eur Urol*. 2015 Sep;68(3):506-15, (Impact Factor (2015) 14.97)
 - **Kroeger N***, Seligson DB*, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2alpha. *Eur J Cancer*. 2014 May;50(8):1531-40. (Impact Factor (2014): 5.42) *(NK and DBS contributed equally)
 - **Kroeger N**, Choueiri TK, Lee JL, et al: Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. *Eur Urol*. 2014 Jun;65(6):1086-92. (Impact Factor (2014): 13.93)
 - **Kroeger N**, Xie W, Lee JL, Bjarnason GL, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DYC. Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Targeted Therapy Agents Characterization of Survival Outcome and Application of the International mRCC Database Consortium Criteria. *Cancer*. 2013 Aug 15;119(16):2999-3006. (Impact Factor (2013): 5.20)
 - **Kroeger N**, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinar FF, Belldegrun AS, Pantuck AJ. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. *Cancer*. 2012; 118: 1795-802. (Impact Factor (2012): 5.02)
 - **Kroeger N**, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Zomorodian N, Kabbinar FF, Belldegrun AS, Pantuck AJ. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. *Eur Urol*. 2012; 61: 888-95. (Impact Factor (2012): 12.48)
 - **Kroeger N**, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclercq N, Remzi M, Zomorodian N, Kabbinar FF, Belldegrun AS, Pantuck AJ. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: A multicenter investigation. *J Urol*. 2012; 187: 418-23. (Impact Factor (2012): 4.02)
 - **Kroeger, N.**, Klatte, T., Chamie, K., Rao, P.N., Birkhauser, F.D., Sonn, G.A., Riss, J., Kabbinar, F.F., Belldegrun, A.S., and Pantuck, A.J. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. *Cancer*. 2013, Apr 15; 119(8):1547-54. doi: 10.1002/cncr.27947. Epub 2013 Jan 18. (Impact Factor (2013): 5.20)

Co-Author (Peer reviewed original publications)

1. Second author

- Harshman LC, **Kroeger N**, Rha SY, et al. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the international metastatic renal cell carcinoma database consortium. *Clinical genitourinary cancer*. 2014;12(5):335-40. (Impact Factor: 1.43)
- McKay RR, **Kroeger N**, Xie W, et al: Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. *Eur Urol*. 2014 Mar;65(3):577-84. (Impact Factor (2014): 13.93)
- Klatte T, **Kroeger N**, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbavar FF, Belldegrun AS, and Pantuck AJ. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. *Cancer*. 2012 Dec 1;118(23):5777-82. (Impact Factor (2012): 5.02)
- Ko JJ*, Xie W*, **Kroeger N**, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. *Lancet Oncol*. 2015 Mar;16(3):293-300. *KJJ and XE contributed equally first. (Impact Factor (2015): 26.51)

2. Additional Co-Authorships

- Huang RR, Chen Z, **Kroeger N**, Pantuck A, Said J, Kluger HM, Shuch B, Ye H. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2024 Apr;22(2):347-353. doi: 10.1016/j.clgc.2023.12.003. Epub 2023 Dec 13. PMID: 38195301
- Lebacle C, Pooli A, Shuch B, Rao N, Chamie K, **Kroeger N**, Faiena I, Liu S, Wood EL, Belldegrun A, Drakaki A, Pantuck AJ. *Cancer*. Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma. *Invest*. 2024 Jan;42(1):97-103. doi: 10.1080/07357907.2024.2308172. Epub 2024 Feb 5. PMID: 38314786
- Büttner F.A., Winter S., Stühler V, Rausch S, Hennenlotter , Füssel S, Zastrow S , Meinhardt M , Toma M, Jerónimo C, Henrique R, Gonçalves VM, **Kröger N**, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M and Schaeffeler E. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy, *Genome Medicine* (2022) 14:105 <https://doi.org/10.1186/s13073-022-01105-y>
- Gellert M, Richter E, Mostertz J, Kantz L, Masur K, Hanschmann EM, Ribback S, **Kroeger N**, Schaeffeler E, Winter S, Hochgräfe F, Schwab M, Lillig CH. The cytosolic isoform of glutaredoxin 2 promotes cell migration and invasion. *Biochim Biophys Acta Gen Subj*. 2020

Jul;1864(7):129599. doi: 10.1016/j.bbagen.2020.129599. Epub 2020 Mar 12.
PMID: 32173377 (Impact Factor 3.442)

- Muroi MR, Ribback S, Sotgiu G, **Kroeger N**, Sadari L, Angius A, Cossu-Rocca P, De Miglio MR. Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma. *Int J Mol Sci*. 2021 Aug 14;22(16):8747. doi: 10.3390/ijms22168747. PMID: 34445451 (Impact Factor 4.556)
- Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, **Kroeger N**, Kanavaran R, Reaume MN, Canil C, Choueiri TK, Heng DY. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. *JAMA Netw Open*. 2021 Jan 4;4(1): e2021869. doi: 10.1001/jamanetworkopen.2020.21869. PMID: 33475752 (Impact Factor 8.48)
- Klatte T, Gallagher KM, Afferi L, Volpe A, **Kroeger N**, Ribback S, McNeill A, Riddick ACP, Armitage JN, 'Aho TF, Eisen T, Fife K, Bex A, Pantuck AJ, Stewart GD. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. *BMC Med*. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1. PMID: 31578141 (Impact Factor 3.153)
- Kaymakalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, **Kroeger N**, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer*. 2016 Feb 1;122(3):411-9. (Impact Factor (2015): 5.65)
- Ribback S, Cigliano A, **Kroeger N**, Pilo, M. G., Terracciano, L., Burchardt, M., Bannasch, P., Calvisi, D. F., Dombrowski, F. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. *Oncotarget*. 2015;6: 13036-13048. (Impact Factor (2015): 6.36)
- Kyriakopoulos E.K., Chittoria N., Choueiri T.K., **Kroeger N**. et al. Outcome of Patients with Metastatic Sarcomatoid Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Clin Genitourin Cancer*. 2015 Apr;13(2): e79-85. (Impact Factor (2015): 2.56)
- Ko JJ, Choueiri TK, Rini BI, Lee JL, **Kroeger N**, Srinivas S, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. *Br J Cancer*. 2014 Apr 15;110(8):1917-22. (Impact Factor (2014): 5.61)
- Freedland SJ, Carducci M, **Kroeger N**, et al: A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. *Cancer Prev Res (Phila)* 6:1120-7, 2013 (Impact Factor (2013): 5.30)
- Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinnavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. Dendritic cell-based immunotherapy in prevention and

treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM.CAIX in immunocompetent mouse models. *J Immunother.* 2013 Feb;36(2):102-11. (Impact Factor (2013): 3.46)

- Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. *Cancer journal* 19, 189-196. (Impact Factor (2013): 3.20)
- Stope MB, Schubert T, Staar D, Ronnau C, Streitborger A, **Kroeger N**, Zimmermann U, Walther R, Burchardt M. Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells. *World J Urol.* 2012; 30: 327-31. (Impact Factor (2012): 2.72)

Peer reviewed reviews

- Ivanyi P, Grulich C, **Kroeger N**, Gauler T, Johannsen M, Bedke J, Grünwald V; Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). Interdisciplinary working group on renal tumors (IAG-N) of the German Cancer Society (DKG). *J Cancer Res Clin Oncol.* 2020 Nov;146(11):3075-3078. doi: 10.1007/s00432-020-03341-4. Epub 2020 Aug 20. PMID: 32816108 (Impact Factor 4.322)
- Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. Hegemann M, **Kroeger N**, Stenzl A, Bedke J. *World J Urol.* 2018 Jun;36(6):849-854. doi: 10.1007/s00345-018-2215-9. Epub 2018 Feb 10. PMID: 29429069 (Impact Factor 2.761)
- Kunath, F., Schmidt, S., Krabbe, L.M., Miernik, A., Dahm, P., Cleves, A., Walther, M., and **Kroeger, N.** 2017. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. *Cochrane Database Syst Rev* 5:CD012045.
- Klatte T*, **Kroeger N***, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ. The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. *World J Urol.* 2014;32(3):597-605. (Impact Factor (2014): 2.67) *(TK and NK contributed equally)
- **Kroeger N**, Belldegrun AS, Pantuck AJ. Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale, Pre-Clinical and Clinical Data. Evidence-Based Complementary and Alternative Medicine (eCAM). 2013; 2013:701434. doi: 10.1155/2013/701434. Epub 2013 (Impact Factor (2013): 2.18)

First Author (Peer reviewed case report)

- **Kroeger N**, Gajda M, Zanow J, Petersen I, Settmacher U, Wunderlich H, Steiner T. Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects. *Urol Int*. 2010; 84: 479-84.

First Author/Co-Author (none peer reviewed review)

- **Kroeger N.**, Burchardt M. Adjuvante Therapie und Rezidivrisiko des Nierenzellkarzinoms. *UroForum* 05/2022.
- **Kroeger N.**, Früherkennung des Prostatakarzinoms mittels PSA Testung: Überlegungen zur Evidenzlage. *UroForum* 05/2020.
- **Kroeger N**, Pantuck A. Second-Line Hormonal Therapies for Prostate Cancer. *Renal and Urology News*. 2011:20-2.
- Zimmermann U, **Kröger N**. Übersicht–Therapie von Hodentumoren. *TumorDiagnostik & Therapie*. 2014;35(01):22-4.

First Author (edited book chapters)

- Birkhäuser FD*, **Kroeger N***, Pantuck AJ. Etiology of RCC: Incidence, Demographics, and Environmental Factors. In: Rini BI, Campbell SC, editors. *Renal Cell Carcinoma: Clinical Management*. New York: Springer Science and Business Media; 2013: 3 - 22.
- **Kroeger N**, Heng D.Y., Kattan M.W., editor. *Independent Predictors of Clinical Outcomes and Prediction Models*: Springer; 2014.

First Author (Editorials / Comments)

- **Kroeger N**, Zimmermann U, Burchardt M, Pantuck AJ. Prognostication in localised renal cell carcinoma. *Lancet Oncol*. 2015;16: 603-604.
- **Kroeger N**, Belldegrün AS, Pantuck AJ. The contemporary role on surgery in the management of renal masses. *World J Urol*. 2014 Jun;32 (3):571-2.
- **Kroeger N**, Editorial Comment to Renal function after radical nephrectomy: Development and validation of predictive models in Japanese patients. *Int J Urol*, 2013
- **Kroeger N**, Zimmermann U, Burchardt M. One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: Time to move toward RCC cure. *Int J Cancer*. 2014 Sep 17.
- **Kroeger N**, Pantuck AJ. Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2014.04.007>. *Eur Urol*. 2014 Oct;66(4):e69-

Published peer reviewed abstracts

- Luna J., Otte im Kampe, Aga-Barfknecht H., Lehne M., Kunk L, Hänsel I, Trescher, Mevius A., Kisser A., **Kröger N.**, De Santis M. Real-world treatment patterns and adherence to Bacillus Calmette-Guérin therapy in high-risk Non-Muscle Invasive Bladder Cancer patients: a retrospective analysis of German health claims data, Die Urologie, Suppl. DGU asbstracts 2025
- **Kroeger N**, Lebacle C, Hein J, Rao PN, Nejati R, Wei S, Burchardt M, Drakaki A, Strother M, Kutikov A, Uzzo R, Pantuck AJ. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. DGU Congress 2022, Hamburg, Die Urologie, Suppl. 3, S.144
- Lebacle CM, Pooli A, Rao N, Wood EL, **Kroeger N**, Liu S, Faiena I, Chamie K, Belldegrun AS, Shuch B, Drakaki A, Pantuck AJ (2019) Prognostic value of gain of chromosome 5q in localized renal cell carcinoma. Journal of Clinical Oncology 37:623-623
- Lebacle CM, Pooli A, Rao N, Wood EL, **Kroeger N**, Liu S, Faiena I, Chamie K, Belldegrun AS, Shuch B, Drakaki A, Pantuck AJ (2019) Prognostic value of loss of chromosome 10q in patients with localized renal cell carcinoma. Journal of Clinical Oncology 37:626-626
- Lebacle CM, Pooli A, Rao N, Wood EL, **Kroeger N**, Kim HJ, Faiena I, Liu S, Chamie K, Belldegrun AS, Shuch B, Drakaki A, Pantuck AJ (2019) The UCLA Histo-Genetic Risk Classification (U-HGRC) to predict outcomes of localized clear cell renal cell carcinoma. Journal of Clinical Oncology 37:627-627
- Lebacle CM*, **Kroeger N***, Pooli A, Liu S, Chamie K, Belldegrun AS, Shuch B, Drakaki A, Pantuck AJ (2019) Improving the definition of high-risk patients for tumor recurrence from clear cell renal cell carcinoma: The U-CISS classification. Journal of Clinical Oncology 37:629-629, *shared first
- **Kroeger N**, Haoran L, GuillermoDe V, Donskov F, Sim H. W., Stühler V, Wells C.J, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Heng DY. Active smoking is associated with worse prognosis in metastatic renal cell carcinoma patients treated with targeted therapies. Der Urologe, Suppl. 1 2018, S. 524
- A. Steven, **N. Kroeger**, S. Leisz, S. Fussek, B. Nowroozizadeh, J. Huang, D. Brandstetter, B. Dougall, M. Burchardt, A. Belldegrun, B. Seliger, A. Pantuck. Receptor activator of NFκB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. European Urology Supplements 16(3): e1721-e1722 March 2017
- M. Skibbe, K. Guenther, P. Kapur, J. Huang, A. Belldegrun, M. Burchardt, U. Zimmermann, Y.-F. Gu, N. Wolff, J. Brugarolas, C. Lillig, A. Pantuck, **N. Kroeger**. Validation of BRCA1 associated protein-1 (BAP-1) as an adverse prognostic factor and investigations into the impact of BAP1 loss on the vascular endothelial growth factor (VEGF) pathway in clear cell renal cell carcinoma (ccRCC). European Urology Supplements 16(3):e1721-e1722 March 2017
- Faiena I, **Kroeger N**, Fussek S, Astrow S, Jain R, Bot A, Drakaki A. Melanoma-Associated

Antigen-A And Programmed Death-Ligand 1 Expression In Urothelial Carcinoma, The Journal of Urology 197(4):e637 April 2017

- Li H*, **Kroeger N***, Velasco V, Donskov F, Sim HW, Wells JC, Stukalin I, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK and Heng DY. The Impact of Active Smoking on Survival Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy. (NK and HL contributed equally first) J Clin Oncol 34, 2016 (suppl 2S; abstr 552)
- **Kroeger N**, Fussek S, Dougall WC, Branstetter D, Nowroozizadeh B, Huang J, Belldgrun AS, Pantuck AJ. Expression of receptor activator of NF- κ B (RANK) in primary clear cell renal cell carcinoma (ccRCC) tissue is an adverse prognostic factor for survival outcome and metastatic spread, Der Urologe, Supplement 1, 2015 p. 82.
- **Kroeger N**, Kapur P, Huang J, Belldgrun A, Brugarolas J, Pantuck A. MP47-06 BRCA1 associated protein-1 (BAP-1) loss in ccRCC: Molecular correlations and validation as a prognostic factor. AUA Meeting, 2015, New Orleans, The Journal of Urology. 2015;193: e554.
- **Kroeger N**, Diesing K, Stope MB, Keller J, Adler F, Hartwig Ch, Asse E, Lillig CH, Ribback S, Walther R, Zimmermann U, Burchardt M. Wild type (wt) TP53 is unable to induce apoptosis in clear cell renal cell carcinoma (ccRCC), DGU Meeting 2014, Düsseldorf, Urologe A, Supplement 1. 2014, 22-23
- **Kroeger N**, Pantuck AJ, Wells C, Mitchell N, Broom R, Kim J, Srinivas S, Yim J, Bjarnason G, Templeton A, Knox J, Smoragiewicz M, Lee J, Rini BI, Vaishampayan U, Wood L, Benoit B, Donskov F, Choueiri TK, Heng DY. Characterizing the Impact of Lymphatic Spread on Survival Outcome of renal cell carcinoma (RCC) patients treated with targeted therapies. DGU Meeting 2014, Düsseldorf, Der Urologe, Supplement 1, 2014, p.115.
- **Kroeger N**, Lee, J.-L., Bjarnason, G.A., Knox, J.J., MacKenzie, M.J., Vaishampayan, U.N., Wood, L., Srinivas, S., Rha, S.Y., Pal, S.K., *et al.* (2013b). Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy. ASCO Meeting Abstracts 31, 4578.
- **Kroeger N**, Xie W, Lee J-L, et al: Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes. ASCO Meeting Abstracts 31:396, 2013
- **Kroeger N**, Seligson DB, Signoretti S, et al: Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma. ASCO Meeting Abstracts 31:387, 2013
- McKay RR, **Kroeger N**, Xie W, et al: Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC). ASCO Meeting Abstracts 31:394, 2013
- **Kroeger N**, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbavar FF, Belldgrun AS, and Pantuck AJ. Clinical, Molecular, and

Genetic Correlates of Lymphatic Spread in Clear Cell Renal Cell Carcinoma, Atlanta, GA, May 19-23th, 2012, J Urol, 187(4), suppl e233.

- Walter, M, Attila S, **Kroeger N**, Bode C, Steiner T, Kniemeyer O, Zipfel P, Romics I, Grimm MO, Junker K. Prediction of TKI-Therapy Response in Patients with Metastatic Renal Cell Carcinoma by Serum Proteomics. Atlanta, GA, May 19-23th, J Urol, 187(4), suppl e722.
- Freedland S, Garducci M, **Kroeger N**, Partin A, Rao JY, Jin Y, Kerkoutian S, Wu H, Li YF, Creel P, Mundy K, Gurganus R, Fedor H, King S, Heber D, Zhang Y, Pantuck. A Phase II Randomized Controlled Trial of POMX vs. Placebo Prior to Radical Prostatectomy. Atlanta, GA, May 19-23th, 2012, J Urol, 187(4), suppl e73.
- Klatte T, **Kroeger N**, Rampersaud EN, Birkhaeuser FD, Logan J, Sonn G, Riss J, Rao PN, Kabbinavar F, Belldgrun AS, Pantuck AJ. Gain of Chromosome 8q is associated with Metastasis and poor Survival of Patients with Clear Cell Renal Cell Carcinoma. Atlanta, GA, May 19-23th, 2012, J Urol, 187(4), suppl e179.
- Birkhäuser FD, Koya RC, Neufeld C, Lu X, Micewicz ED, Chodon T, Atefi M, **Kroeger N**, Dendritic Cell-Based Ad-GMCAIX Immunotherapy in Prevention and Intervention Renal Cell Carcinoma Immunocompetent Mouse Models: Efficacy, Safety, and Mechanism. 103rd Annual Meeting of American Association of Cancer Research, 2012 March 31 – April 4, Chicago, IL.: Cancer Res; April 2012: 1563.
- **Kroeger N**, Klatte T, Birkhaeuser FD, Rampersaud EN, Seligson DB, Zomrorodian N, Kabbinavar FF, Belldgrun AS and Pantuck AJ. The effect of tobacco exposure in renal cell carcinoma (RCC) overall and cancer-specific survival, JCO, 29 (15)_suppl, 2011: 4578
- Walter M., **Kroeger N.**, Steiner Th., von Eggeling F., Driesch D., Wunderlich H., Junker K. Proteomic patterns in serum from patients with metastatic renal cell carcinoma for prediction of targeted therapy response, JCO, 28 (15)_suppl, 2010: e15090.

Invited Presentations at Conferences

02/2026	Highlight-Sitzung: Therapie des Nierenzellkarzinoms: Aktueller Stand und Ausblick, Deutscher Krebsskongress Berlin
02/2026	Debatte: Zytoreduktive Nephrektomie beim Nierenzellkarzinom. Sitzungsvorsitz und Einführungsvortrag zum Thema. Aktueller Stand und Ausblick, Deutscher Krebsskongress Berlin
09/2025	Aktive Überwachung beim Nierenzellkarzinom: wen, wann, und wie? Kongress der Deutschen Gesellschaft für Urologie e.V. Stuttgart 2025
11/2022	Metastasen Chirurgie in Abhängigkeit prognostischer Faktoren. Deutscher Krebsskongress, Berlin
06/2022	Gibt es einen Stellenwert für die neoadjuvante / adjuvante Therapie beim Nierenzellkarzinom? Nordkongress Urologie e.V., Erfurt
09/2021	Wir müssen reden: Patientenindividuelle Systemtherapie des RCC- Patientenindividuelle Systemtherapie des RCC – Eine Fallbasierte

- Expertendiskussion. Kongress der Deutschen Gesellschaft für Urologie e.V. Stuttgart 2021
- 02/2020 Interaktive Tumorkonferenz: Metastasiertes Nierenzellkarzinom, Deutscher Krebskongress Berlin
- 03/2019 Das metastasierte Nierenzellkarzinom-Neue Chancen of Heilung? Sequenz- oder Kombinationstherapie, Metastasierte Karzinome in der Uro-Onkologie zwischen neue therapeutischen Ansätzen und Palliativmedzin, Klink
- 01/2019 Immuntherapie in alten und gebrechlichen Patienten: Ein sinnvoller therapeutischer Ansatz?, kontroversen in der Uro-Onkologie, Magdeburg
- 09/2018 ESCAPE: Intelligente Tumorbiologie beim Nierenzellenkarzinom (RCC), Jahrestagung der Deutschen Gesellschaft für Urologie e.V., Dresden 2019
- 06/2018 Neue therapeutische Optionen in der Erstlinientherapie des metastasierten Nierenzellkarzinoms. Kongress der Vereinigung Norddeutscher Urologen e.V., Rheinsberg 2018
- 02/2018 Terminieren Molekulare Subtypen des Nierenzellkarzinoms das Ergebnis der Therapie?, Deutscher Krebskongress Berlin
- 01/2018 Immuntherapie in der Uro-Onkologie, Hausärztestammtisch Greifswald, Greifswald
- 10/2017 Aktuelle Studien in der Immunonkologie zum mCRPC: Wie ist der Stand, was ist zu erwarten?, Onkologischer Workshop Magdeburg
- 06/2017 Immuntherapie vs. TKI: Pro Immuntherapie, VNU Kongress Rostock, 2017
- 06/2016 Update Systemische Therapie beim metastasierten Nierenzellkarzinom-Wer? Was? Wann?, Nordkongress Urologie, Berlin 2016
- 04/2016 Validierung der mikrovaskulären und lymphovaskulären Invasion als prognostische Marker des Nierenzellkarzinoms in drei deutschsprachigen akademischen Zentren., Meeting of the German RCC Network, Saarbrücken 2016
- 04/2016 Checkpoint-Inhibitoren als neue Substanzklasse – helfen sie bei jedem Tumorleiden?, Klink 2016
- 02/2016 Neues Therapiekonzept Immunonkologie: Die Wunderwaffe beim metastasierten Nierenzellkarzinom?! Wintersymposium, Hamburg 2016
- 12/2015 Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma (RCC) in the Era of Targeted Therapy, CE Alken Meeting, Rottach-Egern 2015
- 10/2015 Die Checkpoint-Inhibition als neuer immunonkologischer Therapieansatz zur Behandlung des metastasierten Nierenzellkarzinoms., BMS Board Meeting, Hamburg 2015
- 06/2015 Die Renaissance der Immuntherapie beim metastasierten Nierenkarzinom: Molekulare Grundlagen, präklinische Evidenz und aktuelle Studienlage der "next generation immunotherapies", VNU Kongress, Hannover, 2015
- 12/2014 Die Therapie des metastasierten nicht-klarzelligen Nierenzellkarzinom (NZK) im Zeitalter molekularer Tumorthherapie: Charakterisierung des Erkrankungsverlaufs

	und Validierung des Heng-Models als Prognosemodell, CE Alken Meeting, Köln 2014
09/2014	Characterizing the Impact of Lymphatic Spread on Survival Outcome of renal cell carcinoma (RCC) patients treated with targeted therapies., Jahrestagung der Deutschen Gesellschaft für Urologie, Düsseldorf, 2014
04/2014	Active Surveillance bei kleinen Nierenzellkarzinomen?, Urologische Fortbildung, Klink 2014
03/2014	Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy. Meeting of the German RCC Network, Saarbrücken 2014
03/2014	Wild type (wt) TP53 is unable to induce apoptosis in clear cell renal cell carcinoma (ccRCC)., Meeting of German RCC Network, Saarbrücken 2014
05/2013	“Poor Prognosis and Advanced Clinicopathological features of Clear Cell Renal Cell Carcinoma (ccRCC) are Associated with Cytoplasmic Subcellular Localization of HIF-2 α .” Meeting of the American Urological Association, San Diego 2013, USA
01/2013	Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes. Canadian Kidney Cancer Forum (CKCF), 2013, Toronto, ON, Canada
12/2012	Clinical, Molecular, and Genetic Correlates of Lymphatic Spread in Clear Cell Renal Cell Carcinoma C.E. Alken Meeting 2012, Munich
06/2012	[„Operieren oder Kontrollieren: Active Surveillance bei kleinen Nierentumoren“], Uro-Stammtisch Nordost, Greifswald 2012, Germany
02/2010	[„Herausforderungen Multiresistenter Nosokomialer Infektionen“] Interdisziplinärer Workshop Infektiologie in der Urologie, Jena 2010
12/2009	[„Tyrosinkinase Inhibitor Therapie: Eine Zwischenbilanz nach 4 Jahren Anwendung in Jena“] Update Renal Cell Carcinoma, Jena 2009

Poster presentations (first-author)

Annual Meeting of the American Society of Clinical Oncology/ Genitourinary ASCO

- **Kroeger, N. (Chicago 2013).** Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy.
- **Kroeger N (Orlando 2013)** Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.

- **Kroeger N (Orlando 2013)** Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma.
- **Kroeger N (Chicago 2011)** The effect of tobacco exposure in renal cell carcinoma (RCC) overall and cancer-specific survival.

Annual Meeting of the American Urological Association

- **Kroeger N (Atlanta 2012)** Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Annual Meeting of the European Association of Urology

- **Kroeger N (Munich 2016)** Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies.
- **Kroeger N (Madrid 2015)** Characterizing the Impact of Lymph Node Metastases on Survival Outcome of metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies.
- **Kroeger N (Mailand 2013)** High cytoplasmic and low nuclear expression of HIF-2 α are associated with worse cancer specific survival (CSS) in clear cell renal cell carcinoma.
- **Kroeger N (Mailand 2013)** Outcomes of patients with non-clear cell renal cell carcinoma treated with targeted therapy and prognostication using the International mRCC Database Consortium Criteria